Kalpit Patel
Stock Analyst at B. Riley Securities
(1.97)
# 3,132
Out of 5,140 analysts
71
Total ratings
40.82%
Success rate
-6.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $117 | $70.74 | +65.39% | 6 | Dec 22, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $5 → $3 | $0.93 | +222.06% | 6 | Nov 25, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Peer Perform | n/a | $12.25 | - | 1 | Nov 18, 2025 | |
| CORT Corcept Therapeutics | Initiates: Peer Perform | n/a | $36.31 | - | 1 | Nov 18, 2025 | |
| JANX Janux Therapeutics | Initiates: Peer Perform | n/a | $13.27 | - | 1 | Nov 18, 2025 | |
| TNGX Tango Therapeutics | Initiates: Peer Perform | n/a | $12.51 | - | 1 | Nov 18, 2025 | |
| ACLX Arcellx | Initiates: Peer Perform | n/a | $68.87 | - | 1 | Nov 18, 2025 | |
| SMMT Summit Therapeutics | Initiates: Peer Perform | n/a | $16.85 | - | 1 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $42 | $46.05 | -8.79% | 1 | Nov 18, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Outperform | $75 | $43.56 | +72.18% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $117.53 | -36.19% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $107.16 | +2.65% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $8.87 | +35.29% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $6.90 | +102.90% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $22.88 | +61.71% | 1 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $37.64 | -36.24% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.34 | +161.19% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $6.36 | +41.51% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.08 | +64.47% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $8.66 | +361.89% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.64 | +82.93% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $32.29 | -38.06% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $3.75 | +700.00% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $20.52 | +75.44% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.33 | +3,762.66% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.60 | +1,025.00% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.58 | +216.46% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $12.28 | +714.33% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $31.47 | +138.32% | 2 | Sep 3, 2021 |
Kymera Therapeutics
Dec 22, 2025
Maintains: Buy
Price Target: $80 → $117
Current: $70.74
Upside: +65.39%
PDS Biotechnology
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.93
Upside: +222.06%
ORIC Pharmaceuticals
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $12.25
Upside: -
Corcept Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $36.31
Upside: -
Janux Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $13.27
Upside: -
Tango Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $12.51
Upside: -
Arcellx
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $68.87
Upside: -
Summit Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $16.85
Upside: -
Scholar Rock Holding
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $46.05
Upside: -8.79%
Soleno Therapeutics
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $43.56
Upside: +72.18%
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $117.53
Upside: -36.19%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $107.16
Upside: +2.65%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $8.87
Upside: +35.29%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $6.90
Upside: +102.90%
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $22.88
Upside: +61.71%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $37.64
Upside: -36.24%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.34
Upside: +161.19%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $6.36
Upside: +41.51%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $6.08
Upside: +64.47%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $8.66
Upside: +361.89%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.64
Upside: +82.93%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $32.29
Upside: -38.06%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $3.75
Upside: +700.00%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $20.52
Upside: +75.44%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.33
Upside: +3,762.66%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.60
Upside: +1,025.00%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.58
Upside: +216.46%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $12.28
Upside: +714.33%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $31.47
Upside: +138.32%